In order to demonstrate the efficacy and safety of SGLT-2 inhibitors for patients with heart failure, this study was conducted to provide a systematic aggregation of evidence from several meta-analyses into a single, current database that is easily accessible. Here, SLC5A2 is linked to heart failure.